Clinical Trials Browser

Recruiting × Melanoma × poly ICLC × Clear all

NCT05098210 2026-03-12

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Phase 1 Recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis